AAAmir Ashoorzadeh

Amir Ashoorzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Ashoorzadeh has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A cryptic allosteric pocket shapes isoform‐selective inhibition of human malic enzymes

    by Ben A. Krinkel, Yuliana Yosaatmadja, Mark D. Slayton, Anita Krinkel, Jack Copping, Jin Heon Jeon, Joyce Eu, Kerslee Kohagen, Amir Ashoorzadeh, Jeff Smaill, et al.

    Malic enzymes (ME) regulate central carbon metabolism and cellular redox balance, and the mitochondrial isoform ME2 is frequently upregulated in aggressive cancers to support metabolic flexibility and stress resistance. Isoform‐selective inhibition has remained out of reach because the catalytic machinery is essentially invariant across the three human enzymes (ME1–3), suggesting that selectivity must arise elsewhere than the active site. Here, we define matched kinetic and regulatory profiles for all three isoforms, highlighting key differences in substrate and cofactor dependence and metabolic regulation. Our x‐ray crystal structures show that the active‐site inhibitor 3′,6′‐dihydroxy‐4,4″‐dimethoxy‐[1,1′:4′,1″‐terphenyl]‐2',5'‐dione (NPD‐389) occupies a conserved, metal‐coordinating pose in all three isoforms, explaining its non‐selective inhibition observed in enzyme assays. We further identify a cryptic pocket adjacent to the active site that is engaged by our probe molecule, flavianic acid (FLA), and accessible only in the mitochondrial enzymes ME2 and ME3. FLA binding locks an open, inactive enzyme conformation in place, with kinetic studies revealing isoform‐specific allosteric responses and suggesting that this pocket may be a native regulatory site sensitive to the mitochondrial metabolic state. Our cellular viability assays suggest that molecules exploiting this cryptic pocket reduce proliferation in cancer cell models with elevated ME2 expression. Conformational dynamics, rather than sequence divergence at the catalytic center, can therefore generate isoform‐specific regulatory and inhibitory mechanisms within a conserved enzyme family.

  • Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

    by Dean C. Singleton, Alexandra M. Mowday, Chris P. Guise, Sophie P. Syddall, Sally Y. Bai, Dan Li, Amir Ashoorzadeh, Jeff B. Smaill, William R. Wilson, Adam V. Patterson

    Advances in the field of cancer immunotherapy have stimulated renewed interest in adenoviruses as oncolytic agents. Clinical experience has shown that oncolytic adenoviruses are safe and well tolerated but possess modest single-agent activity. One approach to improve the potency of oncolytic viruses is to utilise their tumour selectivity to deliver genes encoding prodrug-activating enzymes. These enzymes can convert prodrugs into cytotoxic species within the tumour; however, these cytotoxins can interfere with viral replication and limit utility. In this work, we evaluated the activity of a nitroreductase (NTR)-armed oncolytic adenovirus ONYX-411NTR in combination with the clinically tested bioreductive prodrug PR-104. Both NTR-expressing cells in vitro and xenografts containing a minor population of NTR-expressing cells were highly sensitive to PR-104. Pharmacologically relevant prodrug exposures did not interfere with ONYX-411NTR replication in vitro. In vivo, prodrug administration increased virus titre and improved virus distribution within tumour xenografts. Colonisation of tumours with high ONYX-411NTR titre resulted in NTR expression and prodrug activation. The combination of ONYX-411NTR with PR-104 was efficacious against HCT116 xenografts, whilst neither prodrug nor virus were active as single agents. This work highlights the potential for future clinical development of NTR-armed oncolytic viruses in combination with bioreductive prodrugs.


  • Open Access

    Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

    by Alexander M.A. van der Wiel, Victoria Jackson-Patel, Raymon Niemans, Ala Yaromina, Emily Liu, Damiënne Marcus, Alexandra M. Mowday, Natasja G. Lieuwes, Rianne Biemans, Xiaojing Lin, et al.

    Hypoxia-activated prodrugs (HAP) are a promising class of antineoplastic agents that can selectively eliminate hypoxic tumor cells. This study evaluates the hypoxia-selectivity and antitumor activity of CP-506, a DNA alkylating HAP with favorable pharmacologic properties. Stoichiometry of reduction, one-electron affinity, and back-oxidation rate of CP-506 were characterized by fast-reaction radiolytic methods with observed parameters fulfilling requirements for oxygen-sensitive bioactivation. Net reduction, metabolism, and cytotoxicity of CP-506 were maximally inhibited at oxygen concentrations above 1 μmol/L (0.1% O2). CP-506 demonstrated cytotoxicity selectively in hypoxic 2D and 3D cell cultures with normoxic/anoxic IC50 ratios up to 203. Complete resistance to aerobic (two-electron) metabolism by aldo-keto reductase 1C3 was confirmed through gain-of-function studies while retention of hypoxic (one-electron) bioactivation by various diflavin oxidoreductases was also demonstrated. In vivo, the antitumor effects of CP-506 were selective for hypoxic tumor cells and causally related to tumor oxygenation. CP-506 effectively decreased the hypoxic fraction and inhibited growth of a wide range of hypoxic xenografts. A multivariate regression analysis revealed baseline tumor hypoxia and in vitro sensitivity to CP-506 were significantly correlated with treatment response. Our results demonstrate that CP-506 selectively targets hypoxic tumor cells and has broad antitumor activity. Our data indicate that tumor hypoxia and cellular sensitivity to CP-506 are strong determinants of the antitumor effects of CP-506.


  • Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy

    by Elsie M. Williams, Michelle H. Rich, Alexandra M. Mowday, Amir Ashoorzadeh, Janine N. Copp, Christopher P. Guise, Robert F. Anderson, Jack U. Flanagan, Jeff B. Smaill, Adam V. Patterson, et al.

    Gene-directed enzyme prodrug therapy (GDEPT) uses tumor-tropic vectors to deliver prodrug-converting enzymes such as nitroreductases specifically to the tumor environment. The nitroreductase NfsB from Escherichia coli (NfsB_Ec) has been a particular focal point for GDEPT and over the past 25 years has been the subject of several engineering studies seeking to improve catalysis of prodrug substrates. To facilitate clinical development, there is also a need to enable effective non-invasive imaging capabilities. SN33623, a 5-nitroimidazole analogue of 2-nitroimidazole hypoxia probe EF5, has potential for PET imaging exogenously delivered nitroreductases without generating confounding background due to tumor hypoxia. However, we show here that SN33623 is a poor substrate for NfsB_Ec. To address this, we used assay-guided sequence and structure analysis to identify two conserved residues that block SN33623 activation in NfsB_Ec and close homologues. Introduction of the rational substitutions F70A and F108Y into NfsB_Ec conferred high levels of SN33623 activity and enabled specific labeling of E. coli expressing the engineered enzyme. Serendipitously, the F70A and F108Y substitutions also substantially improved activity with the anticancer prodrug CB1954 and the 5-nitroimidazole antibiotic prodrug metronidazole, which is a potential biosafety agent for targeted ablation of nitroreductase-expressing vectors.


  • 2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors

    by Xueqiang Li, Christopher P. Guise, Rana Taghipouran, Yuliana Yosaatmadja, Amir Ashoorzadeh, Woo-Kyong Paik, Christopher J. Squire, Shuang Jiang, Jinfeng Luo, Yong Xu, et al.


  • Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy

    by Janine N. Copp, Alexandra M. Mowday, Elsie M. Williams, Christopher P. Guise, Amir Ashoorzadeh, Abigail V. Sharrock, Jack U. Flanagan, Jeff B. Smaill, Adam V. Patterson, David F. Ackerley


  • Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy

    by Alexandra M. Mowday, Amir Ashoorzadeh, Elsie M. Williams, Janine N. Copp, Shevan Silva, Matthew R. Bull, Maria R. Abbattista, Robert F. Anderson, Jack U. Flanagan, Christopher P. Guise, et al.


  • Open Access

    Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

    by Christopher P. Guise, Alexandra M. Mowday, Amir Ashoorzadeh, Ran Yuan, Wan-Hua Lin, Dong-Hai Wu, Jeff B. Smaill, Adam V. Patterson, Ke Ding

    Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs. Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy. To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors. These hypoxia-activated prodrugs, including nitro compounds, N-oxides, quinones, and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygen-sensitive manner to form cytotoxins. Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clinical evaluation. In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs. We also describe the current knowledge of how each prodrug class is activated and detail the clinical progress of leading examples.


  • Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966

    by Guo-Liang Lu, Amir Ashoorzadeh, Robert F. Anderson, Adam V. Patterson, Jeff B. Smaill